Zacks Research Analysts Increase Earnings Estimates for PBYI

Puma Biotechnology, Inc. (NASDAQ:PBYI) – Equities research analysts at Zacks Research lifted their FY2025 EPS estimates for Puma Biotechnology in a research note issued to investors on Wednesday, January 22nd. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings of $0.31 per share for the year, up from their prior estimate of $0.28. The consensus estimate for Puma Biotechnology’s current full-year earnings is $0.31 per share. Zacks Research also issued estimates for Puma Biotechnology’s Q4 2026 earnings at ($0.01) EPS and FY2026 earnings at $0.12 EPS.

Other equities analysts have also issued reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Puma Biotechnology in a report on Monday, December 23rd. StockNews.com lowered shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Friday, December 6th.

Puma Biotechnology Stock Down 2.0 %

Shares of NASDAQ:PBYI opened at $2.96 on Monday. The business has a fifty day moving average of $3.06 and a two-hundred day moving average of $2.99. The company has a quick ratio of 1.40, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. The stock has a market cap of $145.31 million, a P/E ratio of 6.17 and a beta of 1.10. Puma Biotechnology has a 52-week low of $2.22 and a 52-week high of $7.73.

Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.10. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. The business had revenue of $80.50 million during the quarter, compared to analyst estimates of $71.32 million. During the same period in the prior year, the business earned $0.12 earnings per share.

Insider Transactions at Puma Biotechnology

In other news, insider Jeffrey Jerome Ludwig sold 9,437 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total value of $29,726.55. Following the completion of the transaction, the insider now owns 108,951 shares of the company’s stock, valued at approximately $343,195.65. This trade represents a 7.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Alan H. Auerbach sold 33,841 shares of Puma Biotechnology stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total transaction of $106,599.15. Following the completion of the transaction, the chief executive officer now owns 7,029,674 shares of the company’s stock, valued at $22,143,473.10. This trade represents a 0.48 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 23.70% of the company’s stock.

Hedge Funds Weigh In On Puma Biotechnology

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PBYI. Gateway Wealth Partners LLC acquired a new stake in shares of Puma Biotechnology in the fourth quarter valued at $31,000. SG Americas Securities LLC acquired a new stake in Puma Biotechnology in the 3rd quarter valued at about $34,000. Franklin Resources Inc. acquired a new position in shares of Puma Biotechnology during the third quarter worth about $41,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Puma Biotechnology during the third quarter worth approximately $44,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Puma Biotechnology during the second quarter worth approximately $58,000. Hedge funds and other institutional investors own 61.29% of the company’s stock.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.